CD39 靶点蛋白|抗体药物|临床药物信息

CD39信息

英文名称：Ectonucleoside triphosphate diphosphohydrolase 1
中文名称：外核苷三磷酸二磷酸水解酶-1
靶点别称：CD39 Antigen，CD39，EC 3.6.1.5，NTPDase-1，NTPDase 1，ATPDase，SPG64，EC:3.6.1.5，Ecto-ATPase 1，Lymphoid cell activation antigen，ENTPD1，Ectonucleoside Triphosphate Diphosphohydrolase 1，Ecto-ATPDase 1，Ecto-Apyrase，Ecto-ATP diphosphohydrolase 1，EC 3.6.1

上市药物数量：0
临床药物数量：5
最高研发阶段：临床二期

CD39产品列表

筛选结果

产品库

在线 (5)

物种

标签

属性

Protein (5)

标记

货号	物种	产品描述
CD9-H52H4	Human	Human CD39 / ENTPD1 Protein, His Tag (active enzyme)
CD9-H82E5	Human	Biotinylated Human CD39 / ENTPD1 Protein, His,Avitag™ (active enzyme)
CD9-H5253	Human	Human CD39 Protein, Mouse IgG2a Fc Tag (active enzyme)
CD9-C52H3	Cynomolgus	Cynomolgus CD39 / ENTPD1 Protein, His Tag (MALS verified) (active enzyme)
CD9-M52H3	Mouse	Mouse CD39 / ENTPD2 Protein, His Tag (MALS verified)

CD9-H52H4|Human CD39 / ENTPD1 Protein, His Tag (active enzyme)

136XXXXXXX6

17人赞

购买蛋白用于测试CD39封闭性抗体封闭CD39水解ATP的功能实验。通过系列梯度CD39抗体与一定浓度的CD39（0.5ug/ml）孵育，再加入50uM ATP,用CTG检测，得到很好的曲线。证明该蛋白具有很好的ATP酶水解功能。
2019-11-11

CD9-H52H4|Human CD39 / ENTPD1 Protein, His Tag (active enzyme)

180XXXXXXX9

3人赞

购买CD39用于动物免疫、后续抗体筛选和检测。抗原蛋白通过检测，纯度、活性方面都非常好，目前已准备免疫，期待获得良好的免疫效果。
2021-12-09

CD9-C52H3|Cynomolgus CD39 / ENTPD1 Protein, His Tag (MALS verified) (active enzyme)

180XXXXXXX9

2人赞

Cynomolgus CD39用于免疫血清效价检测及后续抗体筛选，前期检测血清效价结果较为理想，期待后续的抗体筛选取得好结果
2022-01-10

CD39 分子别名

CD39,ENTPD1,NTPDase 1,Entpd1,Ecto-ATPDase 1,Ecto-ATPase 1

CD39 分子背景

CD39 is also known as Ectonucleoside triphosphate diphosphohydrolase 1, ENTPD1, NTPDase 1, Ecto-ATPDase 1, in the nervous system, could hydrolyze ATP and other nucleotides to regulate purinergic neurotransmission. Could also be implicated in the prevention of platelet aggregation by hydrolyzing platelet-activating ADP to AMP. Hydrolyzes ATP and ADP equally well. NTPDase-1 was originally described as CD39, a B lymphocyte cell surface marker, but it is also present on the surface of natural killer cells, T cells, and some endothelial cells.Regulatory T cells(Tregs) mediate immunosuppression through multiple, non-redundant, cell-contact dependent and independent mechanisms, a growing body of evidence suggests an important role for the CD39-CD73-adenosine pathway. CD39 ectonucleotidase is the rate-limiting enzyme of a cascade leading to the generation of suppressive adenosine that alters CD4 and CD8 T cell and natural killer cell antitumor activities.

CD39 前沿进展

CD39临床药物信息

英文名称	研发代码	研发阶段	公司	适应症	临床试验
ES-002	ES-002	临床一期	科望（上海）生物医药科技有限公司	实体瘤, 肿瘤	详情
ES-002023(Elpiscience Biopharma)		临床一期	科望（上海）生物医药科技有限公司	实体瘤	详情
PUR-001	PUR-001		Purinomia Biotech Inc		详情
ES-014	ES-014	临床一期	科望（上海）生物医药科技有限公司	实体瘤, 肿瘤	详情
SRF-617	SRF-617		Surface Oncology		详情
IPH-5201	IPH-5201	临床二期	Inserm, Orega Biotech	肺癌	详情
TTX-030	TTX-030		Tizona Therapeutics, 艾伯维		详情
JS-019	JS-019	临床一期	北京恩瑞尼生物科技股份有限公司	实体瘤, 淋巴瘤	详情

会议日历

会议一览

CD39